Dyne Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-178.56Mn |
Net Profit Margins | -Inf% |
Dyne Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Dyne Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Dyne Therapeutics, Inc. Common Stock’s net profit fell -61.07% since last year same period to $-178.56Mn in the Q2 2026. On a quarterly growth basis, Dyne Therapeutics, Inc. Common Stock has generated -47.75% fall in its net profits since last 3-months.
Dyne Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Dyne Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.74 |
EPS Estimate Current Year | -0.74 |
Dyne Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.74 - a 5.13% jump from last quarter’s estimates.
Dyne Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.74.
Key Ratios
Earning Per Share (EPS) | -1.08 |
Dyne Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -11.34% since last year same period to -1.08 in the Q2 2026. This indicates that the Dyne Therapeutics, Inc. Common Stock has generated -11.34% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-07-29 | -0.74 | -1.08 | -45.95% |
2026-05-11 | -0.78 | -0.73 | 6.41% |
